Prostatakarzinom: Apalutamid verlängert metastasenfreies Überleben
- PMID: 30731495
- DOI: 10.1055/a-0770-2761
Prostatakarzinom: Apalutamid verlängert metastasenfreies Überleben
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Comment on
-
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Clinical Trial.
Similar articles
-
Metastasiertes Prostatakarzinom: Apalutamid mit lebensverlängernder Wirkung.Aktuelle Urol. 2020 Feb;51(1):10. doi: 10.1055/a-0962-6290. Epub 2020 Feb 4. Aktuelle Urol. 2020. PMID: 32018324 German. No abstract available.
-
Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer.N Engl J Med. 2019 Jul 4;381(1):84-86. doi: 10.1056/NEJMe1905891. N Engl J Med. 2019. PMID: 31269371 No abstract available.
-
Re: Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.Eur Urol. 2018 Aug;74(2):236-237. doi: 10.1016/j.eururo.2018.04.010. Epub 2018 Apr 22. Eur Urol. 2018. PMID: 29691083 No abstract available.
-
Apalutamide: First Global Approval.Drugs. 2018 Apr;78(6):699-705. doi: 10.1007/s40265-018-0900-z. Drugs. 2018. PMID: 29626324 Review.
-
Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.Expert Opin Investig Drugs. 2018 Jun;27(6):553-559. doi: 10.1080/13543784.2018.1484107. Epub 2018 Jun 18. Expert Opin Investig Drugs. 2018. PMID: 29856649 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical